News

Ozempic Maker Novo Nordisk Freezes Hiring Amid Ongoing Struggles

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
24/7 Wall St.2h

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma's Path to Dominance

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
Money Morning1h

Novo Nordisk’s Epic Comeback: How It Reclaimed the GLP-1 Throne

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

GLP-1 drugs such as Lilly’s Mounjaro and Novo’s Ozempic linked to lower cancer risk: study

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.
24/7 Wall St.1d

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Aug 2025)

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo to Cut Employee Bonuses in Denmark Due to Slower Growth

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the Eur…

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in ...
Black Enterprise2d

Ozempic Users Suing For Extreme Side Effects, Many Are Going Blind

The legal battle over Ozempic is getting bigger by the day. Multiple lawsuits have been filed against the diabetes-medicine ...